Imcyse

Avenue du Pré-Aily 14
4031 Liège Angleur
BE
Imcyse
Foundation date
10/08/2010
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
Imcyse develops active targeted immune therapies (ImotopesÔ) that locally inhibit the immune cells involved in the destruction of the diseased organ. The targeted approach and memory effect of the Imcyse technology help to prevent and cure diseases with no current therapeutic alternative, caused by disruptions of the immune system without impairing the patient’s immune defences.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
2206 '23
Translational Research in Crops
Event by: VIB
Latest news
More news-
Mithra appoints experienced life sciences executive Christian Homsy* as Chairman
17 hours ago
Read more
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
How garbage disposal clogs in cells can lead to Alzheimer’s
Friday May 26th 2023
Read more
Jobs
More jobs-
30/05/23
Remote, Brussels, Abroad
Executive, Chief Financial Officer - European Operations
Permanent, Freelance
General Inception -
-